Host Dr. Russell Sharp discusses Eli Lilly's recent purchase of a greenhouse site in Katwijk, Netherlands, and explores possible links to botanical sourcing and GLP‑1 weight‑loss drugs. He outlines how the $3 billion investment raises questions about future use, including pharmaceutical manufacturing, botanical ingredients, and impacts on horticulture. The episode also touches on historical examples of plant‑derived medicines, the Nagoya Protocol on sharing benefits from genetic resources, and the wider implications for food demand and greenhouse agriculture. Tune in to hear the latest developments and what to watch for next. https://eutrema.co.uk/shop/fertiliser/liquid-gold-unique-complete-fertiliser/ Wegovy (also semaglutide, approved for weight loss), Mounjaro and Zepbound (tirzepatide, a dual-action drug), and Saxenda (liraglutide) Type 2 diabetes Whoopi Goldberg, Charles Barkley, Amy Schumer, Serena Williams, Oprah Winfrey, and Elon Musk
